Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
As expected, the baseline BMD and T-scores at all three sites were significantly lower in the denosumab group, while no significant differences were observed for the other parameters.Baseline characteristics of the two groupsDenosumab (N = 23)Controls (N = 23)p valueSex (M:F)10:1310:13NsAge (years)61.50 (7.20)61.40 (9.00)NsBMI (kg/m2)23.10 (1.80)24.30 (4.30)NsTBS T-score− 2.59 (1.20)− 1.46 (1.23)0.003T2DM3 (15%)3 (15%)NsHistory of previous haemodialysis14 (61%)17 (74%)NsYears from transplant to baseline DXA; median [IQR]4 [1.5;10]5 [2;11]NsChronic GCs23 (100%)23 (100%)/Treatment with calcimimetics4 (17%)6 (26%)NsTreatment with active vitamin D compounds6 (26%)7 (30%)Ns25OHD (nmol/L)48.6 (26.7)57.2 (37.3)0.067ALP (U/L)83.4 (43.5)77.8 (29.1)NsPTH (pmol/L)13.0 (10.1)18.9 (14.8)NsSerum creatinine (mg/dL)1.31 (0.45)1.27 (0.43)NsLS T-score− 2.70 (1.20)− 1.42 (1.70)0.006TH T-score− 2.35 (0.77)− 1.40 (1.16)0.014FN T-score− 2.58 (0.52)− 1.98 (1.04)0.002Cortical vBMD TH (mg/cm3)678.00 (81.30)734.00 (95.70)0.038Trabecular vBMD TH (mg/cm3)99.70 (37.90)122.00 (39.40)NsCortical vBMD FN (mg/cm3)701.00 (69.20)746.00 (85.00)NsTrabecular vBMD FN (mg/cm3)149.00 (36.50)166.00 (43.80)Nsc.sBMD TH119 (22.3)133 (28.0)Nsc.sBMD FN106 (18.1)111 (21.3)NsCt.th.TH1.75 (0.14)1.79 (1.19)NsCt.th.FN1.57 (0.17)1.53 (1.18)NsCSMI intertrochanteric (cm4)5.07 (2.10)5.35 (2.87)NsData are expressed as mean (SD) or absolute numbers. 25OHD, 25-hytrody vitamin D serum levels; ALP Alkaline phosphatase, BMI Bone mass index, CSMI Cross-sectional moment of inertia, FN Femoral neck, GCs Glucocorticoids, PTH Parathyroid hormone, TBS Trabecular bone score, TH Total hip, vBMD Volumetric bone mineral density, c.sBMD Cortical surface BMD, Ct.th Cortical thickness
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were assessed at baseline and during follow-up using DXA to analyze aBMD at the lumbar spine (LS), total hip (TH), and femoral neck (FN).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Long-Term Changes in Parameters of Bone Quality in Kidney Transplant Recipients Treated with Denosumab
Study design awaiting verification · Calcified Tissue International · 2025
Original publication title
Long-Term Changes in Parameters of Bone Quality in Kidney Transplant Recipients Treated with Denosumab
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Kidney transplant recipients (KTRs) have an elevated fracture risk. While dual-energy X-ray absorptiometry (DXA) is commonly used to assess areal bone mineral density (aBMD), it does not capture all aspects of bone quality. We investigated the long-term effects on bone DXA-derived indices of bone quality in KTRs treated with denosumab and untreated with denosumab. This is a retrospective study, including KTRs treated with denosumab and untreated age and sex-matched KTR controls. DXA-derived parameters, including trabecular bone score (TBS) and 3D-DXA parameters, were measured at the lumbar spine and femur at baseline and after four years.
Hierarchical linear models were used to assess the between-group effect of treatment over time, also adjusting for site-specific aBMDs. We enrolled 23 KTRs treated with denosumab and 23 KTR denosumab-untreated KTRs. Significant between-group differences over time in favor of the denosumab group were observed for TBS (0.843, 95%CI 0.439; 1.248,p < 0.001), trabecular volumetric BMD at the total hip (Tb.vBMD TH) (13.492, 95%CI 1.707; 25.278, p = 0.003), cortical volumetric BMD at the femoral neck (Ct.vBMD FN) (28.766, 95%CI 8.373; 49.158, p = 0.008), cortical surface BMD at the total hip (c.sBMD TH) (10.507, 95%CI 4.140; 16.873,p = 0.002), cortical surface at the femoral neck (c.sBMD FN) (8.795, 95%CI 2.818; 14.771, p = 0.006), and cortical thickness at the total hip (Ct.th.TH) (0.075, 95%CI 0.020; 0.130, p = 0.010).
After adjusting for BMD, the differences on TBS and Ct.vBMD FN and c.sBMD FN remained significant. Denosumab treatment in KTRs was associated with better outcomes in terms of bone quality and geometry parameters, independent of changes in aBMD.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-025-01349-x.
Authors’ abstract
Kidney transplant recipients (KTRs) have an elevated fracture risk. While dual-energy X-ray absorptiometry (DXA) is commonly used to assess areal bone mineral density (aBMD), it does not capture all aspects of bone quality. We investigated the long-term effects on bone DXA-derived indices of bone quality in KTRs treated with denosumab and untreated with denosumab. This is a retrospective study, including KTRs treated with denosumab and untreated age and sex-matched KTR controls. DXA-derived parameters, including trabecular bone score (TBS) and 3D-DXA parameters, were measured at the lumbar spine and femur at baseline and after four years.
Hierarchical linear models were used to assess the between-group effect of treatment over time, also adjusting for site-specific aBMDs. We enrolled 23 KTRs treated with denosumab and 23 KTR denosumab-untreated KTRs. Significant between-group differences over time in favor of the denosumab group were observed for TBS (0.843, 95%CI 0.439; 1.248,p < 0.001), trabecular volumetric BMD at the total hip (Tb.vBMD TH) (13.492, 95%CI 1.707; 25.278, p = 0.003), cortical volumetric BMD at the femoral neck (Ct.vBMD FN) (28.766, 95%CI 8.373; 49.158, p = 0.008), cortical surface BMD at the total hip (c.sBMD TH) (10.507, 95%CI 4.140; 16.873,p = 0.002), cortical surface at the femoral neck (c.sBMD FN) (8.795, 95%CI 2.818; 14.771, p = 0.006), and cortical thickness at the total hip (Ct.th.TH) (0.075, 95%CI 0.020; 0.130, p = 0.010).
After adjusting for BMD, the differences on TBS and Ct.vBMD FN and c.sBMD FN remained significant. Denosumab treatment in KTRs was associated with better outcomes in terms of bone quality and geometry parameters, independent of changes in aBMD.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-025-01349-x.
Publication and source details
Original title: Long-Term Changes in Parameters of Bone Quality in Kidney Transplant Recipients Treated with Denosumab
Francesco Pollastri; Angelo Fassio; Pietro Manuel Ferraro; Stefano Andreola; Giovanni Gambaro; Andrea Spasiano; Chiara Caletti; Lisa Stefani; Matteo Gatti; Paolo Fabbrini; Maurizio Rossini; Isotta Galvagni; Davide Gatti; Giovanni Adami; Ombretta Viapiana
Calcified Tissue International · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di VeronaOpen access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T06:39:26.084876+00:00
DOI: 10.1007/s00223-025-01349-x · PMC11845414